MedWatch

Analyst: Zealand Pharma pipeline will be crucial

US-based investment bank Jefferies puts most stock in Zealand Pharma’s phase III trial of glepaglutide, a potential treatment for short bowel syndrome, when it comes to the company’s future plans.

Photo: Zealand Pharma / PR

The potential of Zealand Pharma’s drug pipeline has been overlooked, according US-based investment bank Jefferies, which maintains its ”buy” recommendation for the biotech company.

The bank’s share price target for Zealand has been lowered, however, from DKK 200 to DKK 180 (USD 29.4 to USD 26.5), a note reads.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs